K-924 Phase III Long Term Study

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 110 participants.

Also called NCT04289662

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 110 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04289662
Other papers using this trial's data
  • Long-term Efficacy and Safety of K-924 Pitavastatin/Ezetimibe Fixed-dose Combination in Patients with Hypercholesterolemia: A Phase III, Multi-center, Open-label Trial Journal of atherosclerosis and thrombosis, 2024-03-01 DOI, PubMed 37722882, PMC10918028 In the PMC Open Access subset under CC BY-NC-SA.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04289662. Non-randomized; no masking; primary purpose treatment. Start 2020-03-23 (actual); primary completion 2021-08-07 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
K-924 Phase III Long Term Study
Condition
Hypercholesterolemia
Intervention (Drug)
K-924 LD
Intervention (Drug)
K-924 HD
Lead sponsor
Kowa Company, Ltd. (class: industry)

Record details

Record id
cardio:ct-nct04289662
Content hash
40d75a7e0bb492b9f807e1f4c0679f8f43dd40953c835a8b6e38b7453608d00f